Abstract
A, PFS and (B) OS in the dose-expansion phase overall (ITT) population; (C) PFS and (D) OS in patients with low CD73 levels, and (E) PFS and (F) OS in patients with high CD73 levels. ITT, intent-to-treat; NC, not calculable.